Pharmacogenomics and gemcitabine.

@article{Rosell2006PharmacogenomicsAG,
  title={Pharmacogenomics and gemcitabine.},
  author={Rafael Rosell and M. T. Carrillo Cobo and Dolores Isla and Carlos Camps and Bartomeu Massut{\'i}},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 Suppl 5},
  pages={v13-16}
}
Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to cisplatin-based chemotherapy of 11 months. No predictive factor of response to cisplatin-based chemotherapy is yet available in clinical practice. The nucleotide excision repair system plays a major role in repairing a variety of distorting lesions, notably platinum-induced DNA adducts. ERCC1 is a leading gene in repairing cisplatin DNA damage. We… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.

Journal of drug metabolism & toxicology • 2011

Similar Papers

Loading similar papers…